Quanta is improving the lives of dialysis patients by providing advanced haemodialysis solutions for use in both the clinic and home. Quanta’s flagship product SC+ is designed to give dialysis patients greater flexibility, convenience and control over the delivery of their life-sustaining renal replacement therapy.
Quanta was looking for a flexible, integratable, and easy-to-use solution for their clinical studies. The SC+ technology enables haemodialysis to be conducted at home, which means that data must be collected from both healthcare professionals and patients away from clinical sites. In addition, data generated by the devices used in the trial, had to be possible to integrate with the clinical study data, without any post-migration.
Quanta is using SMART-TRIAL to collect trial data from healthcare professionals and patients, while also seamlessly integrating device data directly into SMART-TRIAL using the SMART-TRIAL API. Bringing all data together in one intelligent platform, Quanta slashes the time and costs involved in comparing clinical data with operational data.
SMART-TRIAL’s disruptive cloud technology helps Quanta’s clinical trial teams to work faster and significantly reduce the costs of generating and managing clinical and operational data, from our perspective, it is transforming our extended data ecosystem.